Men with high-grade prostate cancer (HGPC) are at greatest risk of disease progression. Clinical risk factors associated with castration-resistant prostate cancer (CRPC), metastases, and prostate cancer-specific mortality (PCSM) were identified in a contemporary HGPC cohort. Clinical data was collected from men diagnosed with Gleason sum (GS) ≥8 at the Greater Los Angeles Veterans Affairs (GLA-VA) Healthcare System between 2000 and 2013. Multivariable competing risks regression analyses assessed progression to CRPC, metastases, and PCSM within three treatment strata. The cumulative incidence of disease progression was calculated at 2, 5, and 10-year time points. Review of 2149 prostate cancer cases yielded 322 with HGPC. Median survival tim...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
Importance: It is unknown how treatment with radical prostatectomy (RP) and adjuvant external beam r...
Purpose: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, ...
Men with high-grade prostate cancer (HGPC) are at greatest risk of disease progression. Clinical ris...
To build a practical model for predicting the progression to castration-resistant prostate cancer (C...
ObjectiveTo investigate predictors of time to metastasis among men treated with androgen deprivation...
BACKGROUND:Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC...
Background: Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. P...
BACKGROUND: Few studies have examined the risk of developing castration-resistant prostate cancer (C...
Aims of the study: There are no known predictive factors of response in men receiving chemotherapy f...
BackgroundIn the prostate-specific antigen (PSA) screening era, approximately 15% of US men still pr...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Objectives The objective of this study is to find clinical variables that predict the prognosis for ...
ObjectivesTo examine whether prostate-specific antigen doubling time (PSADT) correlates with metasta...
Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death b...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
Importance: It is unknown how treatment with radical prostatectomy (RP) and adjuvant external beam r...
Purpose: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, ...
Men with high-grade prostate cancer (HGPC) are at greatest risk of disease progression. Clinical ris...
To build a practical model for predicting the progression to castration-resistant prostate cancer (C...
ObjectiveTo investigate predictors of time to metastasis among men treated with androgen deprivation...
BACKGROUND:Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC...
Background: Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. P...
BACKGROUND: Few studies have examined the risk of developing castration-resistant prostate cancer (C...
Aims of the study: There are no known predictive factors of response in men receiving chemotherapy f...
BackgroundIn the prostate-specific antigen (PSA) screening era, approximately 15% of US men still pr...
BACKGROUND: There is no consensus on the optimal treatment for localized high-risk prostate cancer (...
Objectives The objective of this study is to find clinical variables that predict the prognosis for ...
ObjectivesTo examine whether prostate-specific antigen doubling time (PSADT) correlates with metasta...
Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death b...
Background: Current guidelines recommend androgen deprivation therapy only for men with very high-ri...
Importance: It is unknown how treatment with radical prostatectomy (RP) and adjuvant external beam r...
Purpose: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, ...